PharmaShots | Incisive News in 3 Shots

Subscribe Now

Merck

Merck Reports Results from the P-III (ZENITH) Study of Winrevair (Sotatercept-csrk) for Pulmonary Arterial Hypertension

Merck Reports Results from the P-III (ZENITH) Study of Winrevair (Sotatercept-csrk) for Pulmonary Arterial Hypertension

November 26, 2024

Merck’s Welireg (Belzutifan) Receives Chinese Approval to Treat Certain Types of Von Hippel-Lindau (VHL) Disease-Related Tumors

Merck’s Welireg (Belzutifan) Receives Chinese Approval to Treat Certain Types of Von Hippel-Lindau (VHL) Disease-Related Tumors

November 25, 2024

Merck Reports the Data from P-III Study Assessing Subcutaneous Keytruda with Berahyaluronidase Alfa to Treat Metastatic NSCLC

Merck Reports the Data from P-III Study Assessing Subcutaneous Keytruda with Berahyaluronidase Alfa to Treat Metastatic NSCLC

November 20, 2024

Merck Reports the CHMP’s Positive Opinion of Keytruda Plus CT as a 1L Treatment of Unresectable Non-Epithelioid Malignant Pleural Mesothelioma (MPM)

Merck Reports the CHMP’s Positive Opinion of Keytruda Plus CT as a 1L Treatment of Unresectable Non-Epithelioid Malignant Pleural...

November 18, 2024

Merck Join Forces with LaNova Medicines to Advance LM-299 for Advanced Solid Tumors

Merck Join Forces with LaNova Medicines to Advance LM-299 for Advanced Solid Tumors

November 15, 2024

Merck Reports EC’s Approval of Keytruda for Two New Indications in Gynecologic Cancers

Merck Reports EC’s Approval of Keytruda for Two New Indications in Gynecologic Cancers

October 24, 2024

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us